Suzano closes $1.22B tissue deal as nine-month profit drops 38%
What's the deal? SuzanoDealroom has a profile for this one. Try Dealroom → has acquired a 51% stake in ArbexDealroom has a profile for this one. Try Dealroom →, a global tissue business, for US$1.71B, completing the transaction on July 1, 2026. The purchase, made from Kimberly-Clark, brings 22 production facilities across 14 countries into the Brazilian pulp giant. It creates a third reportable segment for a company long focused on pulp, paper, and packaging.
Why now? Suzano's core pulp market faces mounting pressure from global supply growth, including from China. Adding consumer-facing revenue hedges that volatility.
What's the endgame? Arbex gives Suzano a direct line to global consumer markets and a call option to buy Kimberly-Clark's remaining 49%, exercisable three years from the agreement. S&P estimates Arbex could add about $500 million in annual EBITDA, with a further $175 million in potential synergies over three years.
By the numbers: For the nine months to September 30, 2026, net income fell 38% year over year to US$2.1B from US$3.4B, even as revenue rose 6% to US$10B. The pulp segment delivered US$3.4B in adjusted EBITDA; the new consumer goods arm added US$246M. The profit drop reflects higher costs, integration expenses, and non-cash purchase-accounting charges tied to Arbex.
What could go wrong? The deal pushed net debt to $14.7 billion and reported dollar leverage to 3.7x, from 3.4x on a pro forma basis. Suzano also triggered a 25-basis-point step-up on its 2031 sustainability-linked bonds — to 4.00% from 3.75%, effective June 16, 2026 — after missing greenhouse-gas intensity targets. Integration remains the primary operational focus.
The signal: The trade-off is clear: Suzano is betting diversification and promised efficiencies will outweigh higher leverage and the demands of absorbing a 14-country business. Delivering those gains is now the test.
Read more: panabee.com
Image credit: Plotterpapier
